OKYO Pharma
OKYO
6 hedge funds and large institutions have $1.36M invested in OKYO Pharma in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.13% more ownership
Funds ownership: 2.61% → 2.75% (+0.13%)
11% less capital invested
Capital invested by funds: $1.54M → $1.36M (-$174K)
14% less funds holding
Funds holding: 7 → 6 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$150K |
| 2 |
Cerity Partners
New York
|
+$1.54K |
| 3 |
CA
Continuum Advisory
Eagle,
Idaho
|
+$77 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$49K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22.2K |
| 3 |
Renaissance Technologies
New York
|
-$21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Barclays
London,
United Kingdom
| $1.28M | +$150K | +97,554 | +13% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $30.5K | -$22.2K | -14,474 | -42% |
|
3
HSBC Holdings
London,
United Kingdom
| $20.3K | – | – | – |
|
|
4
Cerity Partners
New York
| $19.8K | +$1.54K | +1,000 | +8% |
|
5
Geode Capital Management
Boston,
Massachusetts
| $18.1K | – | – | – |
|
|
CA
6
Continuum Advisory
Eagle,
Idaho
| $76 | +$77 | +50 | New |
|
|
7
Morgan Stanley
New York
| – | -$49K | -27,692 | Closed |
|
|
8
Renaissance Technologies
New York
| – | -$21K | -11,800 | Closed |
|
OKYO Hedge Fund Activity: Q1 2024 in Review
6 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q1 2024, worth a combined $1.36M — down 11% from $1.54M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of OKYO and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was Barclays, adding an estimated $150K. The largest seller was Morgan Stanley, exiting entirely with an estimated $49K sold.
- 6 institutional investors held OKYO Pharma (OKYO) as of Q1 2024, down from 7 in Q4 2023.
- Funds reported $1.36M of OKYO Pharma stock for Q1 2024, down 11% quarter-over-quarter.
- 1 fund opened new OKYO Pharma positions in Q1 2024 and 2 closed out, a net change of -1 holder.
- The largest OKYO Pharma buyer in Q1 2024 was Barclays, an estimated $150K added.
- The largest OKYO Pharma seller in Q1 2024 was Morgan Stanley, an estimated $49K sold.
Based on aggregated 13F filings for Q1 2024.